Bihari S, Laffey JG, Bersten AD.
Intensive Care Med. 2016 May;42(5):783-786. doi: 10.1007/s00134-016-4291-x. Epub 2016 Mar 15. No abstract available.
PMID: 26980194
About
Vasomune Therapeutics is a private biotechnology company developing Pegevongitide (AV-001), a first-in-class fully synthetic PEGylated peptide targeting the Tie2 receptor. Activation of the Tie2 receptor by Pegevongitide plays a critical role in improving vascular stability, barrier integrity and endothelial quiescence.